Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Enhancing mTOR-targeted cancer therapy

20 Aug 2009

Abstract excerpt

BACKGROUND: The mammalian target of rapamycin (mTOR) has emerged as an attractive cancer therapeutic target. Accordingly, several mTOR inhibitors (e.g., rapamycin and its analogs; rapalogs) are currently being tested in many cancer clinical trials. Despite the encouraging results showing that some rapalogs improved overall survival among patients with metastatic renal-cell carcinoma, the single-agent activity of...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to PI3K/AKT/mTOR signaling in cancer
Share to Renal cell carcinoma treatment
Share to Tuberous Sclerosis Complex Research

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 19694499
DOI: 10.1517/14728220903225008

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 3 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Enhancing mTOR-targeted cancer therapyPMID 19694499Read ↗

Drug discovery targeting the mTOR pathwaySemantic proximity Read ↗

Targeting mTOR as a Cancer Therapy: Recent Advances in Natural Bioactive Compounds and ImmunotherapySemantic proximity Read ↗

Targeting the mTOR Pathway Using Deforolimus in Cancer TherapySemantic proximity Read ↗

The mammalian target of rapamycin signaling pathway: twists and turns in the road to cancer therapy.Semantic proximity Read ↗

Targeting the mammalian target of rapamycin (mTOR): a new approach to treating cancerSemantic proximity Read ↗

Blocking the mTOR pathway: a drug discovery perspectiveSemantic proximity Read ↗

Mutations in TSC1, TSC2, and MTOR Are Associated with Response to Rapalogs in Patients with Metastatic Renal Cell Carcinoma.Semantic proximity Read ↗

Mammalian Target of Rapamycin (mTOR) Signalling Pathway-A Potential Target for Cancer Intervention: A Short OverviewSemantic proximity Read ↗

PI3K/Akt/mTOR Pathway and Its Role in Cancer Therapeutics: Are We Making Headway?Semantic proximity Read ↗

PTEN expression and mutations in TSC1, TSC2 and MTOR are associated with response to rapalogs in patients with renal cell carcinomaSemantic proximity Read ↗

Bi-steric mTORC1 inhibitors induce apoptotic cell death in tumor models with hyperactivated mTORC1Semantic proximity Read ↗

RAD001 Enhances the Potency of BEZ235 to Inhibit mTOR Signaling and Tumor GrowthSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.